The cancer is the one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems. Even though a number of treatment options are available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is still difficult to achieve. Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.
At present, more than 5 CAR-T therapies have been approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). In fact, more than 170 companies are engaged in the development of over 970 early and late-stage CAR-T therapies, worldwide. Moreover, several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,500 patents related to CAR-T cell therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, more than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund product development initiatives, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR-T cell therapy market is likely to witness significant growth in the foreseen future.
Scope of the Report
The “CAR-T Cell Therapy Market (4th Edition) by Target Indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:
- A detailed assessment of the current market landscape of CAR-T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
- An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
- A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
- An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies, considering them to be KOLs, who are actively involved in R&D of CAR-T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
- Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
- An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
- An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
- An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
- A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
- An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell based immunotherapy that is likely to be marketed in the coming years.
- A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
- Elaborate profiles of the several leading players in the domain of CAR-T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of CAR-T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR-T cell therapy market, wherein opportunity has been segmented across [A] target indications (non-hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma), [B] target antigens (CD19, BCMA, CD19 / CD22 and others), Key Players and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain.
The report features detailed transcripts of interviews held with the following individuals:
- Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
- Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
- Miguel Forte (Chief Operating Officer, TxCell)
- Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
- Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
- Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
- Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
- Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
- Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- What are the prevalent R&D trends related to CAR-T cell therapies?
- Which different types of clinical conditions can be treated using CAR-T cell therapies?
- Who are the leading industry and non-industry players in this market?
- In which geographies, extensive research on CAR-T cell therapy is being conducted?
- What kind of partnership models are commonly adopted by industry stakeholders?
- Who are the key investors in the CAR-T cell immunotherapy domain?
- Who are the key opinion leaders / experts from renowned academic and research institutes which can help drive product development efforts in this domain?
- How is the intellectual property landscape for global CAR-T cell therapies likely to evolve in the foreseen future?
- Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture CAR-T cell therapies?
- What are the key factors that are likely to influence the evolution of the CAR-T cell immunotherapies market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the key promotional strategies used by companies having marketed products?
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
Companies Mentioned
- 920th Hospital of Joint Logistics Support Force
- AbbVie Ventures
- AbCellera
- AbCheck
- AbClon
- Abound Bio
- Abzena
- Acabadem Atunizade Hospital
- Acabadem Labcell
- Acibadem University
- ACROBiosystems
- AdAlta
- Adaptimmune Therapeutics
- Adicet Bio
- Adimab
- Affiliated Hospital of Jiangnan University
- Affiliated Hospital of Jiangsu University
- Affiliated Hospital to Academy of Military Medical Sciences
- Affiliated Zhongshan Hospital of Dalian University
- AffyImmune Therapeutics
- AGC Biologics
- Agreen Biotech
- AK (Suzhou) Biomedical
- Alaunos Therapeutics
- Aleta Biotherapeutics
- Alexandria Venture Investments
- Allife Medical Science and Technology
- Allogene Therapeutics
- Alpha Biopharma
- Amgen Ventures
- Anhui Anke Biotechnology
- Anhui Provincial Hospital
- Antion Biosciences
- Appia Bio
- Arbele
- Arcellx
- Astellas Pharma
- Astrazeneca
- Atara Biotherapeutics
- August Pi and Sunyer Biomedical Research Institute
- Aurora Biopharma
- Autolus
- Avencell
- Bambino Gesù Hospital and Research Institute
- Bayer
- Baylor College of Medicine
- Be The Match BioTherapies
- Beam Therapeutics
- Beijing 302 Hospital
- Beijing Biohealthcare Biotechnology
- Beijing Boren Hospital
- Beijing Cancer Hospital
- Beijing Chao Yang Hospital
- Beijing Children's Hospital
- Beijing Doing Biomedical
- Beijing GoBroad Hospital Management
- Beijing HuiNengAn Biotech
- Beijing Immunochina Medical Science & Technology
- Beijing Sanbo Brain Hospital
- Beijing Tsinghua Chang Gung Hospital
- Beike Biotechnology
- Bellicum Pharmaceuticals
- Beth Israel Deaconess Medical Center (BIDMC)
- Bioceltech Therapeutics
- Bio-Gene Technology
- BioLife Solutions
- Bionomics
- BioNTech
- Bioray Laboratories
- Biosceptre
- Bluebird Bio
- Boya Jiyin
- BoYuan RunSheng Pharma (Hangzhou)
- Bristol-Myers Squibb
- Cabaletta Bio
- Cabaret Biotech
- Calibr
- California Institute for Regenerative Medicine (CIRM)
- Cancer Prevention Research Institute of Texas
- Cancer Research Technology
- Cancer Research UK
- Carbiogene Therapeutics
- Caribou Biosciences
- Carina Biotech
- Caring Cross
- Carisma Therapeutics
- CARsgen Therapeutics
- Cartesian Therapeutics
- Cartherics
- Case Comprehensive Cancer Center
- Celgene
- Cell and Gene Therapy Catapult
- Cell Design Labs
- Cellectis
- Cellex Patient Treatment
- CELLforCURE
- CellPoint
- Cellular Biomedicine Group
- Cellvec
- Celularity
- Celyad Oncology
- Center for International Blood and Marrow Transplant Research
- Central South University
- Changhai Hospital
- Chengdu USino Technology Biology
- Children’s Hospital of Philadelphia
- Children's Hospital and Health System Foundation
- Children's Hospital of Fudan University
- Children's Hospital of Philadelphia
- China Immunotech (Beijing) Biotechnology
- China Meitan General Hospital
- China Regenerative Medicine International (CRMI)
- Chinese Academy of Sciences
- Chinese PLA General Hospital
- Chongqing Precision Biotech
- Chongqing Public Health Medical Center
- Chongqing Sidemu Biotech
- Chongqing University Cancer Hospital
- City of Hope Medical Center
- CoIMMUNE
- Cold Spring Harbor Laboratory
- Columbia University
- CRISPR Therapeutics
- Cryoport
- CureSearch for Children's Cancer
- Curocell
- CytoLumina Technologies
- CytoMed Therapeutics
- Cytovia Therapeutics
- DAIICHI SANKYO COMPANY
- Dana-Farber Cancer Institute
- Dartmouth College
- Delenex Therapeutics
- DLR German Aerospace Center
- Dongguan People's Hospital
- East Clinical Center of Oncology
- Eden BioCell
- Editas Medicine
- Eli Lilly
- Elicera Therapeutics
- Elpis Biopharmaceuticals
- Eureka Therapeutics
- Eutilex
- EXUMA Biotech
- Fate Therapeutics
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Fidelity Management & Research
- First Affiliated Hospital of Chengdu Medical College
- First Affiliated Hospital of Harbin Medical University
- First Affiliated Hospital of Wenzhou Medical Univeristy
- First Affiliated Hospital of Wenzhou Medical University
- First Affiliated Hospital of Zhejiang University
- First Affiliated Hospital Xi'an Jiaotong University
- First Hospital of Jilin University
- First People's Hospital of Foshan
- Five Prime Therapeutics
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
- Fondo Social La Caixa
- Formula Pharmaceuticals
- Fosun Pharmaceutical
- Fourth Hospital of Hebei Medical University
- Fraunhofer
- Fred Hutchinson Cancer Research
- Fred Hutchinson Cancer Research Center
- Fudan University
- Fujian Medical University
- Fundamenta Therapeutics
- FutureGen Biopharm
- G Plus Life Sciences
- GE Global Research
- GE Healthcare
- Genentech
- Genus Oncology
- Gilead Sciences
- Glycostem
- GlyTherix
- Gracell Biotechnologies
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Guangdong General Hospital
- Guangdong Zhaotai InVivo Biomedicine
- Guangzhou 8th People's Hospital
- Guangzhou Anjie Biomedical Technology
- Guangzhou First People's Hospital
- H. Lee Moffitt Cancer Center and Research Institute
- Hadassah Medical Organization
- Harvard University
- HCW Biologics
- Hebei Senlang Biotechnology
- Hebei Yanda Ludaopei Hospital
- Hefei Binhu Hospital
- Heidelberg University Hospital
- Henan Cancer Hospital
- Henan Hualong Biotechnology
- Henan Provincial People's Hospital
- Hitachi Chemical Advanced Therapeutics Solutions
- Horizon 2020
- Horizon Discovery Group
- Houston Methodist Hospital
- Hrain Biotechnology
- HuaDao (Shanghai) Biomedical
- Huai'an Second People's Hospital
- Huazhong University of Science and Technology
- Hunan Provincial People's Hospital
- Hunan Yongren Medical Innovation
- Hunan Zhaotai Yongren Biotech
- Hunan Zhaotai Yongren Medical Innovation
- IASO Biotherapeutics
- iCAR Bio Therapeutics
- iCarTAB BioMed
- iCell Gene Therapeutics
- ICON
- IIT MediTech (Jiangsu)
- ImmunoACT
- Imugene
- Inhibrx
- Innovative Cellular Therapeutics
- Innovent Biologics
- Institut Curie
- Institute of Hematology & Blood Diseases Hospital
- Institute of Hematology and Blood Transfusion
- Instituto de Salud Carlos III
- Intellia Therapeutics
- Intrexon
- Invectys
- Janssen
- Jiangsu Province Hospital of Traditional Chinese Medicine
- Jiangyin People's Hospital
- Jichi Medical University Hospital
- Jingjiang People's Hospital
- Jingzhou Central Hospital
- Jonsson Comprehensive Cancer Center
- Juno Therapeutics
- Juventas Cell Therapy
- JW Therapeutics
- KAEDI
- Karolinska Institute
- Kecellitics Biotech
- King's College London
- Kite Pharma (a Gilead Sciences Company)
- Kuur Therapeutics
- Kyverna Therapeutics
- Legend Biotech
- Leucid Bio
- Leukemia & Lymphoma Society
- Leukemia Research Foundation
- Life Technologies
- Lilly Asia Ventures
- Liminatus Pharma
- Living Pharma
- Lonza
- Loyola University Medical Center
- LUMICKS
- Lyell Immunopharma
- MabQuest
- Malaghan Institute of Medical Research
- Marino Biotechnology
- Massachusetts General Hospital
- MaSTherCell
- Max Delbrück Center for Molecular Medicine
- MaxCyte
- Mayo Clinic
- MD Anderson Cancer Center
- Medical College of Wisconsin
- MedImmune
- Medisix Therapeutics
- MediTrust Health
- Memorial Sloan Kettering Cancer Center
- Merck
- Mie University Hospital
- Miltenyi Biomedicine
- Miltenyi Biotec
- Minerva Biotechnologies
- Mink Therapeutics
- Moderna
- MolMed (acquired by AGC Biologics)
- Mustang Bio
- Nanfang Hospital of Southern Medical University
- Nanjing Bioheng Biotech
- Nanjing Children's Hospital
- NantKwest
- Nantong University
- National Cancer Center Research Institute Japan
- National Cancer Institute
- National Heart, Lung and Blood Institute
- National Institutes of Health (NIH)
- National Institutes of Health Clinical Center
- National Taiwan University Hospital
- National University Hospital, Singapore
- Navy General Hospital
- NeoStem
- Ningbo Cancer Hospital
- NIPRO
- Nkarta
- Noile-Immune Biotech
- Notch Therapeutics
- Novartis
- Novartis Venture Fund
- nSAGE
- NSF Engineering Research Center for Cell Manufacturing Technologies
- Oncodesign Biotechnology
- Oncora Medical
- OncoTracker
- Oncternal Therapeutics
- Oncyte
- ONK Therapeutics
- oNKo-innate
- ONO Pharmaceutical
- Opus Bio
- OrbiMed Advisors
- Ospedale Pediatrico Bambino Gesù (OPBG)
- Otsuka Pharmaceutical
- Ottawa Hospital Research Institute
- Outpace Bio
- Overland Pharmaceuticals
- Oxford Biomedica
- Oxford Biotherapeutics
- Oxford MEStar
- panCELLa
- Parker Institute for Cancer Immunotherapy
- Pediatric Brain Tumor Consortium
- Peking Union Medical College Hospital
- Peking University People's Hospital
- Peking University Shenzhen Hospital
- Peking University Third Hospital
- PeproMene Bio
- PersonGen BioTherapeutics
- Peter MacCallum Cancer Centre
- Pfenex
- Pfizer
- PHARMALOG Institut für klinische Forschung
- PhoreMost
- Pieris Pharmaceuticals
- Pierre Fabre
- Pinze Lifetechnology
- PLA General Hospital
- Porton Biologics
- Poseida Therapeutics
- Precigen
- Precision BioSciences
- Pregenen
- ProMab Biotechnologies
- Protheragen
- Qilu Hospital of Shandong University
- RA Capital Management
- Redmile Group
- RedoxTherapeis
- Refuge Biotechnologies
- Regeneron Pharmaceutical
- RenJi Hospital
- resTORbio
- Rockland Immunochemicals
- Roger Williams Medical Center
- Rosewell Park Comprehensive Cancer Center
- Royal Adelaide Hospital Cancer Centre
- Ruijin Hospital
- Sabz Biomedicals
- Sana Biotechnology
- Sangamo Therapeutics
- Sanofi
- Scotia Biologics
- Seattle Children’s Research Institute
- Seattle Children's Hospital
- Seattle Children's Research Institute
- Second Affiliated Hospital of Guangzhou Medical University
- Second Affiliated Hospital of Nanchang University
- Second Affiliated Hospital of Suzhou University
- Second Affiliated Hospital of Xi'an Jiaotong University
- Second Military Medical University
- Second Xiangya Hospital of Central South University
- Servier
- Shangai Cancer Institute
- Shanghai Biomed-Union Biotechnology
- Shanghai Bioray Laboratory
- Shanghai Cell Therapy Group
- Shanghai Changzheng Hospital
- Shanghai Chest Hospital
- Shanghai Children's Medical Center
- Shanghai East Hospital
- Shanghai GeneChem
- Shanghai General Hospital
- Shanghai International Medical Center
- Shanghai Jiao Tong University School of Medicine
- Shanghai Longyao Biotechnology
- Shanghai Ming Ju Biotechnology
- Shanghai OriginCell Therapeutics
- Shanghai PerHum Therapeutics
- Shanghai Pharmaceuticals
- Shanghai Public Health Clinical Center
- Shanghai Simnova Biotechnology
- Shanghai Tong Ren Hospital
- Shanghai Tongji Hospital
- Shanghai Ultra-T Immune Therapeutics
- Shanghai Unicar-Therapy Bio-medicine Technology
- Shanghai Zhongshan Hospital
- Shanxi Province Cancer Hospital
- Shariati Hospital
- Sheba Medical Center
- Shenzhen Binde Biotechnology
- Shenzhen BinDeBio
- Shenzhen Children's Hospital
- Shenzhen Geno-Immune Medical Institute
- Shenzhen Hospital of Southern Medical University
- Shenzhen Institute for Innovation and Translational Medicine
- Shenzhen Second People's Hospital
- Shenzhen University
- ShiJiaZhuang Zhongxi Children Hospital
- Shoreline Biosciences
- Sichuan Kelun-Biotech Biopharmaceutical
- Sichuan University
- Simcere Pharmaceutical
- Sinobioway Cell Therapy
- Sistema and Russian Direct Investment Fund
- Sorrento Therapeutics
- Southern Medical University
- Southwest Hospital
- SpringWorks Therapeutics
- St. Baldrick's Foundation
- St. Jude Children's Research Hospital
- Stage Cell Therapeutics
- Stand Up To Cancer
- Stanford University
- Stony Brook University
- Sun Yat-Sen University
- Syncopation Life Sciences
- Takara Bio
- Takeda Pharmaceutical
- TC BioPharm
- TCRCure Biopharma
- T-Curx
- Tehran University of Medical Sciences
- Tel Aviv Sourasky Medical Center
- Temasek
- Teneobio
- Terumo BCT
- Tessa Therapeutics
- Texas Children's Hospital
- The Affiliated Hospital Of Guizhou Medical University
- The Affiliated Hospital of Xuzhou Medical University
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- The Beijing Pregene Science and Technology
- The Children's Mercy Hospital
- The Faris Foundation
- The First Affiliated Hospital of Anhui Medical University
- The First Affiliated Hospital of Dalian Medical University
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- The First Affiliated Hospital of Kunming Medical College
- The First Affiliated Hospital of Nanchang University
- The First Affiliated Hospital of Nanjing Medical University
- The First Affiliated Hospital of Soochow University
- The First Affiliated Hospital of University of Science and Technology of China
- The First Affiliated Hospital of Zhejiang University
- The First Affiliated Hospital of Zhengzhou University
- The First Affiliated Hospital with Nanjing Medical University
- The First People's Hospital of Changzhou
- The First People's Hospital of Hefei
- The First People's Hospital of Yuhang District
- The First People's Hospital of Yunnan
- The Fourth Hospital of Hebei Medical University
- The General Hospital of Western Theater Command
- The Ohio State University
- The Pregene (ShenZhen) Biotechnology
- The Second Affiliated Hospital of Chongqing Medical University
- The Second Affiliated Hospital of Hainan Medical University
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
- The Second Hospital of Anhui Medical University
- The Second Hospital of Hebei Medical University
- The Second Hospital of Nanjing Medical University
- The Seventh Affilliated Hospital
- The Sixth Affiliated Hospital of Wenzhou Medical University
- The Third People's Hospital of Kunshan
- The Wistar Institute
- ThermoFisher Scientific
- Tianjin Medical University
- Tianjin Medical University General Hospital
- Tianjin Mycure Medical Technology
- Ticaros
- Timmune Biotech
- Tiziana Life Sciences
- Tmunity Therapeutics
- Tongji Hospital
- Tongji University
- TrakCel
- Transgene
- Transposagen Biopharmaceuticals
- TriArm Therapeutics
- Trinity College Dublin
- Tri-Service General Hospital
- Triumph Over Kid Cancer Foundation
- Tsinghua University
- Twist Bioscience
- TxCell
- Ucello Therapeutics
- UCL Business
- UNC Lineberger Comprehensive Cancer Center
- Union Stem Cell & Gene Engineering
- United States Department of Defense
- University College London
- University Health Network
- University of Alberta
- University of Birmingham
- University of California
- University of Colorado
- University of Milano-Bicocca
- University of Minnesota
- University of Munich
- University of North Carolina
- University of Pennsylvania
- University of South Australia
- University of Southern California
- University of Texas
- University of Washington
- University of Washington and Seattle Cancer Care Alliance
- University of Washington Cancer Consortium
- University of Zurich
- Uppsala University
- USHEALTH
- UTC Therapeutics
- UWELL Biopharma
- V Foundation
- VCN Biosciences
- venBio
- Versant Ventures
- Vineti
- ViroMed
- Vitruvian Networks
- Vivo Capital
- Washington University
- Weill Cornell Medical College
- Weill Medical College of Cornell University
- Wellington Zhaotai Therapies
- West China Hospital
- West China Hospital of Sichuan University
- Wugen
- Wuhan Bio-Raid Biotechnology
- Wuhan Sian Medical Technology
- Wuhan Union Hospital
- WuXi AppTec
- X-Body
- Xi'An Yufan Biotechnology
- Xiangya Hospital of Central South University
- Xiangyang Central Hospital
- Xijing Hospital
- Xinhua Hospital
- Xinqiao Hospital
- Xuanwu Hospital
- Xuzhou Medical University
- Yake Biotechnology
- Yamaguchi University
- Yan'an Affiliated Hospital of Kunming Medical University
- Yunnan Cancer Hospital
- Zhejiang Provincial People's Hospital
- Zhejiang Qixin Biotech
- Zhejiang University
- Zhujiang Hospital
Methodology
LOADING...